Luis A. Rodríguez-Rojas

Luis A. Rodríguez-Rojas

Auto-generated profile, based on publicly available information

Luis A. Rodríguez-Rojas

Cellular Physiology and Translational Medicine, Department of Health Sciences, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City, 09310, Mexico; Graduate Program in Experimental Biology, Department of Health Sciences, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City, 09310, Mexico

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025
Verified
Journal Article
Open access
PDF file
LRLuis A. Rodríguez-Rojas
Luis A. Rodríguez-Rojas
LBLeticia Bucio-Ortiz
Leticia Bucio-Ortiz
VSVerónica Souza-Arroyo
Verónica Souza-Arroyo
MGMaría Concepción Gutierrez-Ruiz
María Concepción Gutierrez-Ruiz
Luis Gomez-QuirozLuis Gomez-Quiroz
Luis Gomez-Quiroz
RMRoxana U. Miranda-Labra
Roxana U. Miranda-Labra
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Its prevalence is increasing due to its close relationship with obesity, insulin resistance, and other metabolic disorders. In this context, the gut-liver axis has been identified as a fundamental regulator in the progression of MASLD, integrating metabolic, immunological, and inflammatory signals that influence hepatic homeostasis. This article reviews the interconnection between the intestine and the liver in the onset and progression of MASLD, highlighting the roles of cholesterol and its metabolism, intestinal barrier permeability, microbiota, and hepatic signaling pathways. We analyze how intestinal dysbiosis and alterations in the enterohepatic circulation of bile acids affect cholesterol absorption and metabolism. Furthermore, we address the influence of endotoxin translocation, activation of the innate immune system, and the interaction of key transcription factors on disease progression from steatosis to advanced fibrosis and hepatocellular carcinoma (HCC). Finally, therapeutic strategies, including pharmacological, dietary, and immunomodulation-based approaches, are discussed to regulate cholesterol metabolism, modulate the intestinal microbiota, and restore gut-liver axis homeostasis. Integrating this knowledge could open new perspectives for treating and preventing MASLD, addressing the disease from a broader and multidisciplinary viewpoint.